[Clinical-Biological analyses and electrocardiographic follow-up of 104 cases of plasmodium falciparum malaria treated at Camp Kosseï in N'Djamena (Tchad)].

Objective The aim of this study was to assess the commonly accepted potential effects of Artemisinin-based combinaison therapy (ACT) on repolarization and QT. Method We realized a retrospective study, evaluating epidemiologic, clinical, biological and electrocardiographic data for patients treated for falciparum malaria, between August 31st and November 3rd, 2017 in the Pôle de santé unique on the Camp Kosseï of N'Djamena. Results One hundred and four patients were included (28,6 years old [0 - 75 years], 72% male). All had fever (38,4 °C [36,6 - 41,5 °C]), asthenia, and main symptoms were headache and arthromyalgia (58%). No significant difference was noted after treatment concerning biological data (especially kaliemia: 3.81 versus 3.91 mmol/l, p = 0.154). There was no significant increase of QTc (415.8 versus 421.4 ms, p = 0.89) with the two ACT treatment used and no adverse events. Discussion Population is essentially composed of Chadian men, often partly immunized, that can modify clinical presentation. French soldiers' medical follow up in military operations decreases contra-indications of ACT. Conclusions These results are in favor of a good cardiac tolerance of ACT with piperaquine and it should be proposed not to realize systematic ECG for the French soldiers in external operation when treated with ACT.

[1]  E. Javelle,et al.  Treatment for Uncomplicated Plasmodium falciparum Malaria in French Soldiers Deployed in Sub-Saharan Africa: Gaps Between Policy and Field Practice. , 2018, Military medicine.

[2]  Q. Bassat,et al.  Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in African Infants , 2017, Antimicrobial Agents and Chemotherapy.

[3]  G. Dolo,et al.  Entomological and parasitological parameters of malaria transmission in Douguia, Chad. , 2017, Medecine et sante tropicales.

[4]  F. Binka,et al.  Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana , 2017, PloS one.

[5]  S. Abdulla,et al.  Multi-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with Electrocardiograms , 2016, PloS one.

[6]  S. Abdulla,et al.  Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania , 2015, Malaria Journal.

[7]  Organización Mundial de la Salud Guidelines for the treatment of malaria , 2010 .

[8]  Q. Bassat,et al.  Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial , 2009, PloS one.

[9]  N. White Cardiotoxicity of antimalarial drugs. , 2007, The Lancet. Infectious diseases.